HER-2 CAR-T cells have been shown to promote tumor regression in animal models and to induce no toxicity, promote disease stability, and, given the 6-week stability of these cells, have a long-lasting effect in a phase I/II clinical trial in patients with HER-2 positive sarcoma [93]. The gene discussed is ERBB2; the disease is neoplasm.